Your browser is no longer supported. Please, upgrade your browser.
Settings
KITE Kite Pharma, Inc. daily Stock Chart
KITE [NASD]
Kite Pharma, Inc.
Index- P/E- EPS (ttm)-6.27 Insider Own1.60% Shs Outstand56.93M Perf Week6.97%
Market Cap6.29B Forward P/E- EPS next Y-6.65 Insider Trans-39.43% Shs Float52.57M Perf Month9.80%
Income-313.60M PEG- EPS next Q-1.94 Inst Own87.50% Short Float16.82% Perf Quarter37.17%
Sales26.90M P/S233.90 EPS this Y-134.30% Inst Trans-3.39% Short Ratio6.96 Perf Half Y130.35%
Book/sh15.05 P/B7.34 EPS next Y19.60% ROA-47.00% Target Price90.36 Perf Year114.56%
Cash/sh14.12 P/C7.82 EPS next 5Y- ROE-55.80% 52W Range39.82 - 113.07 Perf YTD146.48%
Dividend- P/FCF- EPS past 5Y- ROI-63.20% 52W High-2.26% Beta-
Dividend %- Quick Ratio10.30 Sales past 5Y- Gross Margin- 52W Low177.55% ATR3.64
Employees447 Current Ratio10.30 Sales Q/Q92.20% Oper. Margin- RSI (14)67.86 Volatility3.30% 3.44%
OptionableYes Debt/Eq0.00 EPS Q/Q-93.90% Profit Margin- Rel Volume0.70 Prev Close112.98
ShortableYes LT Debt/Eq0.00 EarningsAug 07 BMO Payout- Avg Volume1.27M Price110.52
Recom2.30 SMA205.92% SMA5022.80% SMA20064.00% Volume892,816 Change-2.18%
Jul-13-17Downgrade Maxim Group Buy → Hold
Jul-10-17Reiterated Jefferies Buy $101 → $121
May-09-17Reiterated FBR & Co. Outperform $90 → $91
May-09-17Downgrade Wedbush Neutral → Underperform $60 → $54
May-08-17Downgrade Raymond James Outperform → Mkt Perform
Mar-13-17Downgrade Standpoint Research Buy → Hold
Mar-06-17Reiterated RBC Capital Mkts Outperform $85 → $95
Mar-03-17Downgrade Stifel Buy → Hold $74
Mar-02-17Downgrade Citigroup Buy → Neutral
Mar-01-17Reiterated Maxim Group Buy $77 → $84
Feb-28-17Reiterated H.C. Wainwright Buy $78 → $85
Feb-22-17Initiated Wells Fargo Market Perform
Feb-02-17Initiated Wedbush Neutral $46
Jan-04-17Initiated ROTH Capital Buy $68
Nov-21-16Initiated H.C. Wainwright Buy $78
Aug-09-16Reiterated Maxim Group Buy $87 → $77
Jul-13-16Reiterated Stifel Buy $63 → $74
Jun-02-16Initiated Raymond James Outperform $61
May-10-16Reiterated Mizuho Buy $90 → $80
Feb-25-16Initiated Citigroup Buy $67
Jul-25-17 06:02AM  3 Key Things Every CAR-T Investor Should Watch Motley Fool
Jul-21-17 08:00AM  Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Kite Pharma Accesswire
Jul-20-17 08:30AM  Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute Business Wire
Jul-19-17 01:30PM  FDA Panel Votes To Approve CTL019, Positive Implications for CYRX Zacks Small Cap Research
Jul-18-17 08:10AM  5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote Zacks
Jul-14-17 07:30AM  [$$] Gormley's Take: Racing Against Time to Defeat Cancer The Wall Street Journal
Jul-13-17 04:49PM  [$$] 3 Drug Stocks That Can Ride Novartis' Coattails Barrons.com
04:24PM  How Novartis' FDA Win In Cancer Also Could Be A Boon For Its Rivals Investor's Business Daily
10:30AM  Is Juno Therapeutics Stock Still a Strong Buy? Motley Fool
06:00AM  T-cell cancer therapy holds promise, longer-term results await Reuters
Jul-12-17 05:28PM  A cancer treatment that one expert called the 'most exciting thing Ive seen in my lifetime' just got closer to approval Business Insider
05:08PM  Novartis Grabs Key FDA Panel Approval Of Experimental Cancer Drug Investor's Business Daily
03:28PM  A revolutionary experimental cancer treatment just got one step closer to approval Business Insider
Jul-11-17 02:19PM  FDA Decision on Novartis Gene Therapy Drug Could Benefit Kite Pharma TheStreet.com
01:20PM  FDA Moves On Novartis Gene Therapy May Be Good For Kite Pharma Barrons.com
Jul-10-17 02:44PM  ETFs with exposure to Kite Pharma, Inc. : July 10, 2017 Capital Cube
Jul-07-17 03:00AM  Sophies Choice for Oncologists: Who Gets New Life-Saving Drug Bloomberg
Jul-06-17 04:25PM  Novartis Faces Key FDA Panel On Cancer Drug; Why Kite Could Be The Winner Investor's Business Daily
Jul-05-17 07:30AM  [$$] Biotechs Race to Unleash Cellular Cancer Therapies The Wall Street Journal
Jul-02-17 07:42AM  Better Buy: Agenus Inc. vs. Kite Pharma Motley Fool
Jun-30-17 04:16PM  Can Celgene, Bluebird Keep Their Lead As Rivals Champ At The Bit? Investor's Business Daily
01:10PM  The Cure For Cancer? Look At Your Blood Investor's Business Daily
10:40AM  Bluebird Bio: Too Much Good News? Barrons.com
08:50AM  After Bluebird's 75% Gain In 2017, Analysts At BTIG Downgrade To Neutral Benzinga
Jun-29-17 03:53PM  M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks Zacks
Jun-28-17 09:32AM  ETF Winner of 1H17 and its Top 5 Stocks Zacks
09:29AM  Global Blood Shares Pop on Priority Designation; Kite Pharma Rises on Patent News: Biotech Movers TheStreet.com
08:30AM  U.S. Patent Office to Confirm Kites Seminal Eshhar CAR-T Patent Business Wire
Jun-27-17 09:30AM  Kite Named to the MIT Technology Reviews Annual 50 Smartest Companies List in Recognition for its Leadership in Establishing CAR-T Therapy Business Wire
08:27AM  Kite Pharma A Top Pick Ahead Of Axi-Cel Launch Benzinga
Jun-23-17 08:04AM  3 Biotech Stocks for Enterprising Investors Motley Fool +7.10%
Jun-22-17 12:19PM  3 Hot Plays in the Resurgent Biotech Sector Investopedia
Jun-21-17 04:43PM  Uber Brings In New PE Shop Director After Bonderman Resignation TheStreet.com
12:42PM  4 Stocks & ETFs to Buy on Clovis' Positive Drug Data Zacks
10:03AM  3 Stocks at 52-Week Highs Still Worth Buying Motley Fool
09:35AM  Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More Zacks
Jun-20-17 04:43PM  These Biotechs Are Leading The Sector To A 3-Month High Today Investor's Business Daily
02:39PM  Biotech Stocks To Watch And Pharma Industry News Investor's Business Daily
07:30AM  [$$] Vineti Takes Aim at Cancer Cell-Therapy Market With $13.8 Million Series A The Wall Street Journal
Jun-19-17 05:37PM  Three must-own cancer stocks for your biotechnology portfolio MarketWatch
09:37AM  Will These Cutting-Edge Cancer Killers Reignite The Biotech Rally? Investor's Business Daily
Jun-16-17 07:41AM  3 Top-Performing Biotech Stocks This Week Motley Fool
Jun-12-17 01:16PM  [$$] Cancer treatment: scaling up a vein-to-vein solution Financial Times
05:15AM  Why Is Kite Pharma (KITE) Up 6.3% Since the Last Earnings Report? Zacks
Jun-09-17 10:10AM  Why is Kite Pharma (KITE) Stock Up Close to 100% this Year? Zacks
09:01AM  Vetr Downgrades Kite Pharma As It Nears Resistance Benzinga
Jun-08-17 04:23PM  Nvidia Stock Could Double In Bull Case; eBay, PayPal Hit Highs On Analysts Investor's Business Daily +5.57%
04:13PM  Small Biotech Pops As Rival Novartis Struggles To Keep Pace Investor's Business Daily
01:31PM  There's a race to get 2 revolutionary new cancer treatments on the market here's who's in the lead Business Insider
12:13PM  BTIG Gets Bullish on Kite Pharma Inc (KITE) and Axi-Cels Pathway to Approval in DLBCL SmarterAnalyst
11:43AM  The Reasons Kite Pharma Is Set to Fly Higher TheStreet.com
10:55AM  Kite Pharma Flies HigherWhy? Barrons.com
10:13AM  Juno Therapeutics: To Sell, Or Not To SellGood Question Barrons.com
09:20AM  Key Reasons BTIG Just Upgraded Kite Pharma Benzinga
08:07AM  Kite Pharma, Inc. breached its 50 day moving average in a Bullish Manner : KITE-US : June 8, 2017 Capital Cube
08:00AM  Today's Research Reports on Stocks to Watch: Kite Pharma and Novavax Accesswire
Jun-07-17 11:36AM  Novartis touts new T-cell therapy data in race for FDA approval Reuters +7.12%
Jun-06-17 06:00PM  Kite Pharma (KITE) Releases Data on Lead Drug for Leukemia Zacks
08:30AM  Kite to Present at June 2017 Investor Conferences Business Wire
Jun-05-17 05:40PM  Kite to launch mid-stage leukemia trial in fourth quarter 2017 Reuters
02:27PM  ETFs with exposure to Kite Pharma, Inc. : June 5, 2017 Capital Cube
09:00AM  Kite to launch mid-stage leukemia trial in fourth quarter 2017 Reuters
09:00AM  Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia Business Wire
09:00AM  Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results TheStreet.com
Jun-02-17 12:49PM  Stocks to watch during ASCO CNBC Videos
09:55AM  Kite Pharma, Inc. :KITE-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
Jun-01-17 07:20AM  A New Era of Cancer Research as ASCO Kicks Off 24/7 Wall St.
May-30-17 07:49AM  Biotech Stock Roundup: Puma Soars on Advisory Panel Vote, Priority Review for Kite Drug Zacks
May-29-17 08:23AM  Kite Pharma Cancer Drug BLA Gets Priority Review Status Zacks
May-26-17 10:47AM  Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel Business Wire
May-25-17 04:21PM  I Still Can't Believe Juno Therapeutics Spent $46.4 Million on This Failed Drug Motley Fool
May-17-17 05:10PM  Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting TheStreet.com -6.69%
05:05PM  Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the 2017 American Society of Clinical Oncology Annual Meeting Business Wire
May-15-17 09:00PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Kite Pharma Inc. Business Wire
03:16PM  This Hedge Funds Picks Returned 52% in Q1 And Youve Never Heard of It Insider Monkey
May-14-17 10:20AM  Insider Buying Soars as Q1 Earnings Wind Up: Tempur Sealy, Apollo Global, Revlon, Kite Pharma and More 24/7 Wall St.
May-12-17 11:15PM  Edited Transcript of KITE earnings conference call or presentation 8-May-17 12:30pm GMT Thomson Reuters StreetEvents
May-11-17 07:03PM  Kite Pharma, Inc. Value Analysis (NASDAQ:KITE) : May 11, 2017 Capital Cube
02:38PM  Insiders Are Loading Up on Kite Pharma, Cliffs Natural Resources and More TheStreet.com
May-10-17 08:30AM  Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death Zacks
May-09-17 03:40PM  CYRX: Biopharma, Clinical Trial Growth, Fuels Another Record Quarter Zacks Small Cap Research
08:58AM  Kite Pharma, Inc. breached its 50 day moving average in a Bearish Manner : KITE-US : May 9, 2017 Capital Cube
08:00AM  Today's Research Reports on Trending Tickers: Celgene and Kite Pharma Accesswire
07:43AM  Kite Pharma (KITE) Posts Q1 Loss, Reveals CAR-T Patient Death Zacks
May-08-17 09:06PM  Edited Transcript of KITE earnings conference call or presentation 8-May-17 12:30pm GMT Thomson Reuters StreetEvents -13.19%
05:51PM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Kite Pharma, Inc. Business Wire
05:17PM  KITE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Kite Pharma, Inc. To Contact The Firm Business Wire
04:36PM  These Drugmakers Plunged On Consensus-Lagging Q1 Sales, Losses Investor's Business Daily
03:00PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Kite Pharma, Inc. Business Wire
01:29PM  KITE Plunges, Take Sector With It Investopedia
01:26PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Kite Pharma, Inc. (KITE) PR Newswire
01:07PM  Kite Pharma Breaks Down & Could Close the Gap Investopedia
12:57PM  Here's What's Dragging Kite Pharma Inc. Down Today Motley Fool
12:14PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kite Pharma, Inc. - KITE PR Newswire
11:46AM  Here's Why Kite Pharma (KITE) Stock Is Plummeting Today Zacks
11:31AM  Analyst: Kite Pharma's CAR-T Patient Death, Stock Selloff Is A Buying Opportunity Benzinga
10:06AM  Kite Pharma Discloses CAR-T Patient Death, Rattling Investors TheStreet.com
09:21AM  Kite Pharma (KITE) Q1 Loss Wider than Expected, Sales Miss Zacks
08:06AM  Kite Pharma reports 1Q loss Associated Press
08:00AM  Kite Reports First Quarter Financial Results Business Wire
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptor (CAR)-based therapy that is in Phase 2 clinical trials for patients with relapsed or refractory aggressive diffuse large B cell lymphoma, primary mediastinal B cell lymphoma, and transformed follicular lymphoma. The company is also conducting a Phase 2 clinical trial of KTE-C19 on patients with relapsed/refractory mantle cell lymphoma; a Phase 1-2 clinical trial of KTE-C19 on adult patients with relapsed/refractory acute lymphoblastic leukemia; and a Phase 1-2 clinical trial of KTE-C19 in pediatric patients with relapsed/refractory, as well as Phase 1b/2 clinical trial of KTE-C19 in combination with Genentech's atezolizumab in patients with refractory DLBCL. In addition, it engages in developing T cell receptors-based therapies, which targets self-antigens, viral antigens, and neo-antigens. The company has a research collaboration and license agreement with Amgen Inc. to develop and commercialize various CAR-based product candidates; cooperative research and development agreements with the U.S. Department of Health and Human Services; a license agreement with Cabaret Biotech Ltd. and National Institutes of Health; a license and research agreement with Alpine Immune Sciences, Inc.; and a research collaboration and license agreement with Cell Design Labs, Inc. Kite Pharma, Inc. was founded in 2009 and is headquartered in Santa Monica, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BUTITTA CYNTHIA MChief Operating OfficerJul 10Option Exercise1.3515,00020,250132,795Jul 11 05:36 PM
BUTITTA CYNTHIA MChief Operating OfficerJul 10Sale103.0915,0001,546,300117,795Jul 11 05:36 PM
Wiezorek JeffreySVP Clinical DevelopmentJul 03Option Exercise6.8910,00068,90031,071Jul 06 06:15 PM
Wiezorek JeffreySVP Clinical DevelopmentJul 03Sale104.3210,0001,043,20121,071Jul 06 06:15 PM
WITTE OWEN N.DirectorJun 26Sale100.6012,5001,257,50076,250Jun 26 07:55 PM
WITTE OWEN N.DirectorJun 23Option Exercise18.0012,500225,000101,250Jun 26 07:55 PM
WITTE OWEN N.DirectorJun 23Sale100.0012,5001,250,00088,750Jun 26 07:55 PM
BUTITTA CYNTHIA MChief Operating OfficerJun 23Sale100.815,000504,033112,795Jun 27 12:25 PM
CHAMPSI FARAHDirectorJun 16Sale88.115,450480,2000Jun 16 05:41 PM
Ruchefsky Steven BDirectorJun 14Sale89.4820,0001,789,574205,426Jun 16 05:43 PM
CHAMPSI FARAHDirectorJun 14Sale90.4015,0001,356,00063,664Jun 16 05:41 PM
BUTITTA CYNTHIA MChief Operating OfficerJun 09Option Exercise1.3510,00013,500127,795Jun 12 07:16 PM
BUTITTA CYNTHIA MChief Operating OfficerJun 09Sale88.5510,000885,491117,795Jun 12 07:16 PM
DOUMANI ROYDirectorJun 08Sale84.535,000422,634150,017Jun 09 09:11 PM
DOUMANI ROYDirectorJun 07Sale84.4610,000844,621155,017Jun 09 09:11 PM
Kim Helen SusanEVP, Business DevelopmentJun 01Option Exercise51.432,400123,43221,064Jun 05 05:05 PM
Kim Helen SusanEVP, Business DevelopmentJun 01Sale72.452,400173,88018,664Jun 05 05:05 PM
JENKINSON PAUL LChief Financial OfficerMay 10Buy72.593,000217,7703,000May 10 03:12 PM
JENKINSON PAUL LChief Financial OfficerMay 10Buy72.5745032,6577,480May 10 03:12 PM
Ruchefsky Steven BDirectorMay 09Buy69.501,40097,300225,426May 10 12:52 PM
BONDERMAN DAVIDDirectorMay 09Buy68.9450,0003,446,9982,408,084May 09 06:29 PM
Nussbaum RanDirectorMay 09Buy69.119,832679,4743,520May 11 02:02 PM
Belldegrun ArieChairman, President and CEOMay 09Buy68.5717,0001,165,69085,507May 09 03:37 PM
Chang David DEVP, R&D, Chief Medical Off.May 01Option Exercise6.8920,000137,80070,165May 03 06:06 PM
Kim Helen SusanEVP, Business DevelopmentMay 01Option Exercise53.902,400129,36021,064May 03 06:08 PM
Kim Helen SusanEVP, Business DevelopmentMay 01Sale82.122,400197,08818,664May 03 06:08 PM
Chang David DEVP, R&D, Chief Medical Off.May 01Sale82.0920,0001,641,74450,165May 03 06:06 PM
CHAMPSI FARAHDirectorApr 28Sale82.592,617216,1384,962May 01 06:52 PM
CHAMPSI FARAHDirectorApr 27Sale82.7716,5511,369,9267,579May 01 06:52 PM
CHAMPSI FARAHDirectorApr 26Sale82.7251,3124,244,59724,130Apr 26 05:38 PM
BUTITTA CYNTHIA MChief Operating OfficerApr 25Option Exercise1.3515,00020,250132,795Apr 27 06:49 PM
BUTITTA CYNTHIA MChief Operating OfficerApr 25Sale81.8515,0001,227,690117,795Apr 27 06:49 PM
CHAMPSI FARAHDirectorApr 25Sale82.8046,7833,873,58575,442Apr 26 05:38 PM
CHAMPSI FARAHDirectorApr 24Sale82.3425,8182,125,854122,225Apr 26 05:38 PM
CHAMPSI FARAHDirectorApr 17Sale82.4843,1013,555,028148,043Apr 17 09:24 PM
CHAMPSI FARAHDirectorApr 13Sale82.3972,2755,954,737191,144Apr 17 09:24 PM
BUTITTA CYNTHIA MChief Operating OfficerApr 03Option Exercise1.355,0006,750122,795Apr 04 04:15 PM
Kim Helen SusanEVP, Business DevelopmentApr 03Option Exercise53.902,400129,36021,064Apr 04 04:16 PM
Chang David DEVP, R&D, Chief Medical Off.Apr 03Option Exercise6.8920,000137,80070,165Apr 04 04:17 PM
Chang David DEVP, R&D, Chief Medical Off.Apr 03Sale81.5420,0001,630,86650,165Apr 04 04:17 PM
Kim Helen SusanEVP, Business DevelopmentApr 03Sale81.802,400196,32018,664Apr 04 04:16 PM
BUTITTA CYNTHIA MChief Operating OfficerApr 03Sale81.965,000409,798117,795Apr 04 04:15 PM
BUTITTA CYNTHIA MChief Operating OfficerMar 27Option Exercise1.3510,00013,500127,795Mar 28 07:57 PM
BUTITTA CYNTHIA MChief Operating OfficerMar 27Sale77.6710,000776,746117,795Mar 28 07:57 PM
BUTITTA CYNTHIA MChief Operating OfficerMar 09Option Exercise1.3521,11828,509138,913Mar 10 05:25 PM
BUTITTA CYNTHIA MChief Operating OfficerMar 09Sale80.7821,1181,705,929117,795Mar 10 05:25 PM
Kim Helen SusanEVP, Business DevelopmentMar 01Option Exercise53.902,400129,36021,064Mar 02 06:05 AM
DOUMANI ROYDirectorMar 01Option Exercise1.3550,00067,50075,065Mar 02 06:06 AM
Wiezorek JeffreySVP Clinical DevelopmentMar 01Option Exercise6.8918,000124,02039,071Mar 02 06:09 AM
BUTITTA CYNTHIA MChief Operating OfficerMar 01Option Exercise1.3528,88238,991146,677Mar 01 09:59 PM
Chang David DEVP, R&D, Chief Medical Off.Mar 01Option Exercise6.8960,000413,400110,165Mar 02 06:08 AM
BUTITTA CYNTHIA MChief Operating OfficerMar 01Sale80.0528,8822,312,004117,795Mar 01 09:59 PM
Kim Helen SusanEVP, Business DevelopmentMar 01Sale75.432,400181,03918,664Mar 02 06:05 AM
Wiezorek JeffreySVP Clinical DevelopmentMar 01Sale75.0118,0001,350,14421,071Mar 02 06:09 AM
DOUMANI ROYDirectorMar 01Sale76.772,800214,94225,065Mar 02 06:06 AM
DOUMANI ROYDirectorMar 01Sale74.0516,0001,184,873115,017Mar 02 06:06 AM
Chang David DEVP, R&D, Chief Medical Off.Mar 01Sale79.1660,0004,749,44150,165Mar 02 06:08 AM
Kim Helen SusanEVP, Business DevelopmentFeb 28Option Exercise52.2747,9002,503,75666,564Mar 02 06:05 AM
Kim Helen SusanEVP, Business DevelopmentFeb 28Sale67.4047,9003,228,37218,664Mar 02 06:05 AM
BUTITTA CYNTHIA MChief Operating OfficerFeb 27Option Exercise1.3510,00013,500127,795Mar 01 09:59 PM
BUTITTA CYNTHIA MChief Operating OfficerFeb 27Sale54.4210,000544,178117,795Mar 01 09:59 PM
Wiezorek JeffreySVP Clinical DevelopmentFeb 01Option Exercise6.891,50010,33522,195Feb 06 04:36 PM
Wiezorek JeffreySVP Clinical DevelopmentFeb 01Sale51.211,50076,82020,695Feb 06 04:36 PM
BUTITTA CYNTHIA MChief Operating OfficerJan 31Option Exercise1.3510,00013,500127,795Feb 01 07:09 PM
BUTITTA CYNTHIA MChief Operating OfficerJan 31Sale50.5610,000505,562117,795Feb 01 07:09 PM
BUTITTA CYNTHIA MChief Operating OfficerJan 06Option Exercise1.3510,00013,500127,795Jan 10 05:03 PM
Wiezorek JeffreySVP Clinical DevelopmentJan 06Option Exercise6.891,50010,33522,195Jan 10 05:04 PM
Wiezorek JeffreySVP Clinical DevelopmentJan 06Sale50.001,50075,00020,695Jan 10 05:04 PM
BUTITTA CYNTHIA MChief Operating OfficerJan 06Sale50.1310,000501,289117,795Jan 10 05:03 PM
Wiezorek JeffreySVP Clinical DevelopmentDec 20Sale50.8671636,41615,095Dec 22 04:53 PM
Tomasello ShawnChief Commercial OfficerDec 20Sale50.864,901249,26549,635Dec 22 04:52 PM
Kim Helen SusanEVP, Business DevelopmentDec 20Sale50.8693647,6058,064Dec 22 04:51 PM
Chang David DEVP, R&D, Chief Medical Off.Dec 20Sale50.861,78890,93825,123Dec 22 04:50 PM
Belldegrun ArieChairman, President and CEODec 20Sale50.863,493177,65424,707Dec 22 04:47 PM
BUTITTA CYNTHIA MChief Operating OfficerDec 20Sale50.862,482126,23592,995Dec 22 04:48 PM
Wiezorek JeffreySVP Clinical DevelopmentDec 01Option Exercise6.891,50010,33517,311Dec 05 07:03 PM
Wiezorek JeffreySVP Clinical DevelopmentDec 01Sale50.761,50076,13415,811Dec 05 07:03 PM
BUTITTA CYNTHIA MChief Operating OfficerNov 25Option Exercise1.3510,00013,500105,477Nov 29 05:02 PM
BUTITTA CYNTHIA MChief Operating OfficerNov 25Sale50.4010,000504,01595,477Nov 29 05:02 PM
Wiezorek JeffreySVP Clinical DevelopmentNov 10Option Exercise6.891,50010,33517,311Nov 14 06:55 PM
BUTITTA CYNTHIA MChief Operating OfficerNov 10Option Exercise1.3510,00013,500105,477Nov 14 06:57 PM
BUTITTA CYNTHIA MChief Operating OfficerNov 10Sale50.6510,000506,46795,477Nov 14 06:57 PM
Wiezorek JeffreySVP Clinical DevelopmentNov 10Sale50.181,50075,27015,811Nov 14 06:55 PM
Wiezorek JeffreySVP Clinical DevelopmentOct 03Option Exercise6.891,50010,33517,311Oct 05 07:44 PM
Wiezorek JeffreySVP Clinical DevelopmentOct 03Sale54.811,50082,21415,811Oct 05 07:44 PM
BUTITTA CYNTHIA MChief Operating OfficerSep 26Option Exercise1.3510,00013,500105,477Sep 28 05:03 PM
BUTITTA CYNTHIA MChief Operating OfficerSep 26Sale54.1310,000541,30095,477Sep 28 05:03 PM
Wiezorek JeffreySVP Clinical DevelopmentSep 01Option Exercise6.891,50010,33517,311Sep 02 06:34 PM
Wiezorek JeffreySVP Clinical DevelopmentSep 01Sale58.241,50087,36215,811Sep 02 06:34 PM
BUTITTA CYNTHIA MChief Operating OfficerAug 25Option Exercise1.3510,00013,500105,477Aug 26 06:38 PM
BUTITTA CYNTHIA MChief Operating OfficerAug 25Sale58.2810,000582,77595,477Aug 26 06:38 PM
Kim Helen SusanEVP, Business DevelopmentAug 15Option Exercise51.432,400123,43211,400Aug 16 08:16 PM
Kim Helen SusanEVP, Business DevelopmentAug 15Sale63.012,400151,2299,000Aug 16 08:16 PM
Kim Helen SusanEVP, Business DevelopmentAug 12Option Exercise51.4333,5001,722,90542,500Aug 16 08:16 PM
Kim Helen SusanEVP, Business DevelopmentAug 12Sale60.0833,5002,012,5969,000Aug 16 08:16 PM
Wiezorek JeffreySVP Clinical DevelopmentAug 01Option Exercise6.891,50010,33516,367Aug 02 06:51 PM
Wiezorek JeffreySVP Clinical DevelopmentAug 01Sale56.901,50085,34314,867Aug 02 06:51 PM